Volume 28, Number 2—February 2022
Dispatch
Postvaccination Multisystem Inflammatory Syndrome in Adult with No Evidence of Prior SARS-CoV-2 Infection
Table
Measure | Reference | Hospital day |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ED visit | 1 | 2 | 4 | 8 | 15 | 22 | 29 | 36 | 39 | 50 | 60 | 64 | 68 | 73 | ||
Leukocyte count, × 103 cells/μL | 3.5−10.0 | 12.2 | 14.7 | 11.7 | 28.4 | 26.5 | 31.9 | 58.9 | 24.3 | 17.4 | 29.1 | 31.5 | 14.2 | 19.0 | 16.0 | 13.4 |
Erythrocyte count, × 106 cells/μL | 4.0−5.4 | 3.8 | 3.2 | 3.1 | 3.9 | 3.1 | 2.9 | 2.9 | 3.3 | 4.1 | 4.3 | 3.9 | 3.5 | 3.8 | 3.6 | 3.7 |
Absolute neutrophil count, × 103/μL | 1.9−7.4 | 11.1 | 13.0 | 10.3 | 27.1 | 24.8 | 31.4 | 54.3 | 22.42 | 14.7 | 26.6 | 19.2 | 12.1 | 15.7 | 13.4 | 10.2 |
Absolute lymphocyte count, × 103 cells/μL | 1.0−3.9 | 0.7 | 0.5 | 0.8 | 0.9 | 0.8 | 0.6 | 2.5 | 1.4 | 1.4 | 2.0 | 0.8 | 1.2 | 2.3 | 1.9 | 2.6 |
Platelet count, × 103 cells/μL | 130–400 | 169 | 159 | 157 | 245 | 168 | 367 | 282 | 274 | 269 | 330 | 177 | 288 | 277 | 182 | 186 |
Hemoglobin, g/dL | 12–16 | 11.2 | 9.6 | 9.3 | 11.9 | 9.3 | 8.5 | 8.4 | 9.4 | 11.6 | 12.0 | 11.4 | 10.2 | 11.1 | 10.5 | 11.0 |
Hematocrit, % | 36–46 | 33.7 | 27.9 | 28.4 | 34.2 | 27.5 | 24.6 | 24.2 | 28.6 | 34.5 | 35.9 | 33.2 | 30.2 | 33.1 | 31.5 | 33.4 |
CRP, mg/dL | 0–0.5 | 30.7 | >40 | 26.4 | 17.3 | 5.6 | 25.3 | 9.5 | 15.0 | 11.8 | 24.2 | 1.5 | 0.3 | 2.3 | ||
Procalcitonin, ng/mL | 0–0.065 | 6.524 | 7.122 | 1.385 | 2.851 | 0.844 | 2.505 | 0.272 | 0.209 | 2.297 | 1.747 | 0.236 | 0.087 | 0.134 | ||
ESR, mm/h | 0–20 | 49 | ||||||||||||||
IL-6, pg/mL | 0–29.4 | 862.6 | 54.6 | 802.1 | 98.1 | 621.1 | 522.1 | |||||||||
Ferritin, ng/mL | 12–60 | 13,241 | 22,860 | 13,710 | 12,455 | >10,000 | 4,918 | 3,595 | ||||||||
Lactic acid, mEq/L | 0.4–0.8 | 1.7 | 1.1 | 1.4 | 1.2 | 1.2 | 0.7 | 1.9 | 0.9 | |||||||
Sodium, mmol/L | 136–145 | 130 | 134 | 139 | 137 | 134 | 131 | 128 | 132 | 137 | 134 | 137 | 138 | 138 | 140 | 141 |
Potassium, mmol/L | 3.5–5.1 | 3.7 | 3.9 | 4.0 | 2.6 | 3.8 | 4.2 | 4.4 | 4.7 | 3.5 | 2.9 | 3.0 | 3.2 | 3.3 | 3.0 | 3.3 |
Chloride, mmol/L | 98–110 | 100 | 108 | 113 | 104 | 101 | 99 | 99 | 102 | 102 | 94 | 98 | 98 | 99 | 99 | 100 |
CO2, mmol/L | 19–24 | 22 | 21 | 17 | 27 | 19 | 26 | 23 | 25 | |||||||
Calcium, mg/dL | 8.4–10.2 | 8.1 | 7.3 | 7.4 | 7.5 | 8.1 | 7.8 | 7.9 | 8.2 | 8.0 | 8.2 | 8.7 | 8.7 | 8.7 | 9.2 | |
Glucose, mg/dL | 70–110 | 114 | 99 | 106 | 94 | 78 | 103 | 121 | 93 | 125 | 81 | 107 | 119 | 105 | 97 | 100 |
BUN, mg/dL | 8–20 | 19.9 | 11.9 | 8.7 | 10.4 | 12.9 | 6.1 | 19.5 | 12.1 | 14.6 | 6.2 | 10.0 | 9.1 | 9.1 | 6.7 | 6.2 |
Creatinine, mg/dL | 0.4–0.8 | 0.77 | 0.43 | 0.38 | 0.38 | 0.28 | 0.25 | 0.26 | 0.17 | 0.21 | 0.23 | 0.21 | 0.25 | 0.32 | 0.33 | 0.33 |
Total protein, g/dL | 6.7–8.3 | 6.1 | 4.9 | 4.3 | 5.1 | 5.6 | 5.8 | 6.3 | 6.7 | 6.5 | 6.3 | 6.6 | 6.9 | 5.9 | 6.5 | |
Albumin, g/dL | 3.8–5.3 | 3.6 | 2.8 | 2.5 | 2.8 | 2.9 | 2.9 | 2.6 | 2.8 | 2.7 | 2.8 | 3.1 | 3.5 | 3.4 | 3.9 | |
Total bilirubin, mg/dL | 0.22–1.2 | 0.89 | 0.30 | 0.44 | 0.77 | 0.53 | 0.51 | 0.71 | 0.40 | 0.77 | 0.43 | 0.69 | 0.62 | 0.72 | 0.77 | |
ALT, U/L | 4–44 | 9 | 7 | 7 | 10 | 18 | 22 | 45 | 45 | 53 | 51 | 55 | 60 | 37 | 26 | |
AST, U/L | 8–38 | 22 | 32 | 31 | 34 | 50 | 43 | 36 | 57 | 50 | 33 | 31 | 54 | 45 | 31 | |
ALP, U/L | 42–98 | 58 | 44 | 65 | 84 | 98 | 103 | 185 | 110 | 130 | 137 | 115 | 102 | 80 | 83 | |
CK, U/L | 43–165 | 33 | 38 | 379 | 20 | 19 | 28 | 23 | 10 | 8 | ||||||
CK-MB, ng/mL | 0.6–6.3 | 1.1 | 1.7 | 6.1 | 0.9 | 0.9 | 1.1 | 1.1 | 0.9 | 0.8 | ||||||
Troponin I, pg/mL | 2.3–17.5 | 88.7 | 94.0 | 286.0 | 6.9 | 4.9 | 4.1 | 2.5 | 2.6 | |||||||
NT-proBNP, pg/mL | 0–125 | 4,736 | 1,707 | 797 | 691 | 8,065 | 1,246 | 1,240 | 1,441 | 177 | 123 | |||||
D-dimer, ng/mL | 0–243 | >3,200 | >3,200 | >3,200 | >3,200 | 2,521 | 1,408 | 362 | 282 | |||||||
FDP, µg/mL | 0–5 | 60.09 | 50.72 | 27.10 | ||||||||||||
Fibrinogen, mg/dL | 238–498 | 578 | 674 | 203 | 326 | |||||||||||
Anti-thrombin III, % | 83–128 | 56 | 47 | |||||||||||||
Protein C activity, % | 70–130 | 58 | 52 | |||||||||||||
Protein S activity, % | 65–140 | 27 | 11 | |||||||||||||
APTT, s | 25.1–39.7 | 34.6 | 33.9 | 33.7 | 33.0 | 34.6 | 29.5 | 30.6 | 31.9 | 23.9 | ||||||
PT, s | 9.4–13.6 | 19.4 | 18.1 | 15.9 | 17.8 | 19.1 | 17.9 | 18.0 | 14.7 | 14.0 | ||||||
INR | 0.80–1.23 | 1.77 | 1.65 | 1.44 | 1.62 | 1.74 | 1.63 | 1.64 | 1.33 | 1.27 | ||||||
Anti-HPF4 antibody | Neg. | Neg. | ||||||||||||||
LDH, U/L | 200–400 | 511 | 1,428 | 1,472 | 1,161 | 1,279 | 1,417 | |||||||||
Rheumatoid factor, IU/mL | 0–18 | 8 | ||||||||||||||
C3, mg/dL | 65–135 | 108 | ||||||||||||||
C4, mg/dL | 13–35 | 19 |
*ALP, alkaline phosphatase; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BUN, blood urea nitrogen; C3, complement 3; C4, complement 4; CK, creatine kinase; CK-MB, creatine kinase-myocardial band; CRP, C-reactive protein; ED; emergency department; ESR, erythrocyte sedimentation rate; FDP, fibrin and fibrinogen-degradation products; IL-6, interleukin 6; INR, international normalized ratio; LDH, lactate dehydrogenase; NT-proBNP, N-terminal–pro B-type natriuretic peptide; PT, prothrombin time.
Page created: December 01, 2021
Page updated: January 23, 2022
Page reviewed: January 23, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.